Results 31 to 40 of about 42,124 (246)

Tamoxifen Resistance: Emerging Molecular Targets [PDF]

International Journal of Molecular Sciences, 2016
17β-Estradiol (E2) plays a pivotal role in the development and progression of breast cancer. As a result, blockade of the E2 signal through either tamoxifen (TAM) or aromatase inhibitors is an important therapeutic strategy to treat or prevent estrogen receptor (ER) positive breast cancer.
Milena Rondón-Lagos, Victoria Villegas, Nelson Rangel, Magda Sánchez, Peter Zaphiropoulos   +4 more
openaire   +2 more sources

miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22

Cellular Physiology and Biochemistry, 2018
Background/Aims: Most of estrogen receptor positive breast cancer patients respond well initially to endocrine therapies, but often develop resistance during treatment with selective estrogen receptor modulators (SERMs) such as tamoxifen.
Jun Li, Mingjie Lu, Jiao Jin, Xiyi Lu, Tongpeng Xu, Shidai Jin   +5 more
doaj   +1 more source

Upregulation of PI3K/AKT/PTEN pathway is correlated with glucose and glutamine metabolic dysfunction during tamoxifen resistance development in MCF-7 cells

Scientific Reports, 2020
Tamoxifen resistance is emerging as a big challenge in endocrine therapy of luminal A breast cancer patients. In this study, we aimed to determine the molecular changes of PI3K/AKT/PTEN signaling pathway during tamoxifen-resistance development using ...
Lama Hamadneh, Rama Abuarqoub, Ala Alhusban, Mohamad Bahader   +3 more
doaj   +1 more source

Intestinal peroxisome proliferator‐activated receptor α‐fatty acid‐binding protein 1 axis modulates nonalcoholic steatohepatitis

Hepatology, EarlyView., 2022
Abstract Background and Aims Peroxisome proliferator‐activated receptor α (PPARα) regulates fatty acid transport and catabolism in liver. However, the role of intestinal PPARα in lipid homeostasis is largely unknown. Here, intestinal PPARα was examined for its modulation of obesity and NASH. Approach and Results Intestinal PPARα was activated and fatty
Tingting Yan, Yuhong Luo, Nana Yan, Keisuke Hamada, Nan Zhao, Yangliu Xia, Ping Wang, Changdong Zhao, Dan Qi, Shoumei Yang, Lulu Sun, Jie Cai, Qiong Wang, Changtao Jiang, Oksana Gavrilova, Kristopher W. Krausz, Daxesh P. Patel, Xiaoting Yu, Xuan Wu, Haiping Hao, Weiwei Liu, Aijuan Qu, Frank J. Gonzalez   +22 more
wiley   +1 more source

A model of estrogen-related gene expression reveals non-linear effects in transcriptional response to tamoxifen [PDF]

, 2012
SynthSys is a Centre for Integrative Systems Biology (CISB) funded by BBSRC and EPSRC, reference BB/D019621/1.Background: Estrogen receptors alpha (ER) are implicated in many types of female cancers, and are the common target for anti-cancer therapy ...
Harrison, David J, Kenneth Macleod, Yamaguchi, Azusa, Macleod, Kenneth, Galina Lebedeva, David J Harrison, Lebedeva, Galina, Langdon, Simon P., Langdon, Simon P, Azusa Yamaguchi, Harrison, David J., Simon P Langdon   +11 more
core   +1 more source

Functional network analysis of p85 and PI3K as potential gene targets and mechanism of oleanolic acid in overcoming breast cancer resistance to tamoxifen

Journal of Genetic Engineering and Biotechnology, 2022
Background Tamoxifen resistance in estrogen receptor positive (ER+) breast cancer therapy increases, which is the leading cause of cancer treatment failure, as it can impair patients’ prognoses, cause cancer recurrence, metastasis, and death. Combination
Wilfan Ibadurrahman, Naufa Hanif, Adam Hermawan   +2 more
doaj   +1 more source

Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer [PDF]

, 2010
Tamoxifen is the most widely prescribed anti-estrogen treatment for patients with estrogen receptor (ER)-positive breast cancer. However, there is still a need for biomarkers that reliably predict endocrine sensitivity in breast cancers and these may ...
Liang, Liang, J Michael Dixon, Muir, Morwenna, David A Cameron, Walker, Graeme, Sims, Andrew H., Morwenna Muir, Liang Liang, Muir, Morwenna; id_orcid, Langdon, Simon P., Dixon, J. Michael, Sims, Andrew, Taylor, Karen J., Dana Faratian, Graeme Walker, Cameron, David A., Simon P Langdon, Dixon, Mike, Karen J Taylor, Taylor, Karen J, Harrison, David J, Barbara Kuske, David J Harrison, Cameron, David A, Faratian, Dana, Kuske, Barbara, Andrew H Sims, Langdon, Simon P, Harrison, David J.   +28 more
core   +1 more source

The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy

Journal of Hematology & Oncology, 2019
Background Tamoxifen resistance remains a clinical challenge for hormone receptor-positive breast cancer. Recently, dysregulations in autophagy have been suggested as a potential mechanism for tamoxifen resistance.
Ji Wang, Shuduo Xie, Jingjing Yang, Hanchu Xiong, Yunlu Jia, Yulu Zhou, Yongxia Chen, Xiaogang Ying, Cong Chen, Chenyang Ye, Linbo Wang, Jichun Zhou   +11 more
doaj   +1 more source

Genome-wide analysis of the FOXA1 transcriptional regulatory network identifies super enhancer associated LncRNAs in tamoxifen resistance

Frontiers in Genetics, 2022
Breast cancer is the leading cause of death in female cancers, and what’s worse, tamoxifen resistance occurs in almost 30% breast cancer patients and has seriously attenuated the therapeutic effect.
Xiulei Zhang, Qian Zhang, Guangzhi Liu
doaj   +1 more source

Cholesterol metabolism and resistance to tamoxifen

Current Opinion in Pharmacology, 2012
The oncoprotein MUC-1 was shown to upregulate the transcription of genes encoding cholesterol and lipid metabolic enzymes and correlated with a resistance to Tamoxifen (Tam) despite the presence of estrogen receptor α in breast cancer tumors. The importance of this observation is supported by molecular studies on Tam suggesting two additional ...
Poirot, Marc, Silvente-Poirot, Sandrine, Weichselbaum, Ralph   +2 more
openaire   +2 more sources